{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:14:38Z","timestamp":1769728478531,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T00:00:00Z","timestamp":1452643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11934-015-0566-y","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T19:55:50Z","timestamp":1452714950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Qiang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene K.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"issue":"6","key":"566_CR1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","volume":"63","author":"M Roupret","year":"2013","unstructured":"Roupret M et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059\u201371.","journal-title":"Eur Urol"},{"issue":"1","key":"566_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-4608(00)00426-X","volume":"127","author":"MA Rigola","year":"2001","unstructured":"Rigola MA et al. Comparative genomic hybridization analysis of transitional cell carcinomas of the renal pelvis. Cancer Genet Cytogenet. 2001;127(1):59\u201363.","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"566_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cancergen.2012.04.008","volume":"205","author":"T Misumi","year":"2012","unstructured":"Misumi T et al. DNA copy number aberrations associated with lymphovascular invasion in upper urinary tract urothelial carcinoma. Cancer Genet. 2012;205(6):313\u20138.","journal-title":"Cancer Genet"},{"issue":"2","key":"566_CR4","first-page":"699","volume":"7","author":"Y Sasaki","year":"2014","unstructured":"Sasaki Y et al. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol. 2014;7(2):699\u2013708.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"566_CR5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos JP et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2015;68(6):970\u20137. This manuscript is the largest series of UTUC tumors profiled using next- generation sequencing and provided the molecular landscape of UTUC and potential actionable genomic targets in UTUC.","journal-title":"Eur Urol"},{"issue":"2","key":"566_CR6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0022-5347(01)62926-4","volume":"160","author":"RH Sijmons","year":"1998","unstructured":"Sijmons RH et al. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol. 1998;160(2):466\u201370.","journal-title":"J Urol"},{"issue":"2","key":"566_CR7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2012.07.047","volume":"63","author":"SC Skeldon","year":"2013","unstructured":"Skeldon SC et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013;63(2):379\u201385.","journal-title":"Eur Urol"},{"issue":"4","key":"566_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","volume":"96","author":"A Umar","year":"2004","unstructured":"Umar A et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"4 Pt 1","key":"566_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.ju.0000086551.22844.cd","volume":"170","author":"N Amira","year":"2003","unstructured":"Amira N et al. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol. 2003;170(4 Pt 1):1151\u20134.","journal-title":"J Urol"},{"issue":"6","key":"566_CR10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.urology.2005.01.019","volume":"65","author":"M Roupret","year":"2005","unstructured":"Roupret M et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65(6):1233\u20137.","journal-title":"Urology"},{"issue":"13","key":"566_CR11","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","volume":"23","author":"JW Catto","year":"2005","unstructured":"Catto JW et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903\u201310.","journal-title":"J Clin Oncol"},{"issue":"15","key":"566_CR12","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1073\/pnas.1002472107","volume":"107","author":"N Valeri","year":"2010","unstructured":"Valeri N et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010;107(15):6982\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"566_CR13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.acuro.2014.03.010","volume":"38","author":"A Garcia-Tello","year":"2014","unstructured":"Garcia-Tello A et al. DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas Urol Esp. 2014;38(9):600\u20137.","journal-title":"Actas Urol Esp"},{"issue":"26","key":"566_CR14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"566_CR15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrurol.2011.92","volume":"8","author":"S Mitchell","year":"2011","unstructured":"Mitchell S, Mayer E, Patel A. Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8(9):516\u201322. This article critically summarizes previous studies of p53 expression in UTUC and highlights the limitations of sample size, methods to detect p53 expression and statistical analyses.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"566_CR16","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2178::AID-CNCR16>3.0.CO;2-T","volume":"79","author":"A Rey","year":"1997","unstructured":"Rey A et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer. 1997;79(11):2178\u201385.","journal-title":"Cancer"},{"issue":"12","key":"566_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1442-2042.2000.00230.x","volume":"7","author":"H Hashimoto","year":"2000","unstructured":"Hashimoto H et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol. 2000;7(12):457\u201363.","journal-title":"Int J Urol"},{"issue":"6","key":"566_CR18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.urology.2004.01.009","volume":"63","author":"R Zigeuner","year":"2004","unstructured":"Zigeuner R et al. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004;63(6):1079\u201383.","journal-title":"Urology"},{"issue":"3","key":"566_CR19","first-page":"1091","volume":"33","author":"YC Lee","year":"2013","unstructured":"Lee YC et al. Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan. Anticancer Res. 2013;33(3):1091\u20138.","journal-title":"Anticancer Res"},{"issue":"5","key":"566_CR20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ijc.2910640503","volume":"64","author":"M Furihata","year":"1995","unstructured":"Furihata M et al. p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Int J Cancer. 1995;64(5):298\u2013303.","journal-title":"Int J Cancer"},{"issue":"2","key":"566_CR21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F","volume":"178","author":"M Furihata","year":"1996","unstructured":"Furihata M et al. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol. 1996;178(2):133\u20139.","journal-title":"J Pathol"},{"issue":"1","key":"566_CR22","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.eururo.2012.04.031","volume":"62","author":"A Bagrodia","year":"2012","unstructured":"Bagrodia A et al. Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. Eur Urol. 2012;62(1):e27\u20139.","journal-title":"Eur Urol"},{"issue":"3","key":"566_CR23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","volume":"55","author":"JM Oers van","year":"2009","unstructured":"van Oers JM et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650\u20137.","journal-title":"Eur Urol"},{"key":"566_CR24","first-page":"65","volume":"4","author":"SR Lyle","year":"2012","unstructured":"Lyle SR et al. Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis. Res Rep Urol. 2012;4:65\u20139.","journal-title":"Res Rep Urol"},{"issue":"3","key":"566_CR25","first-page":"1043","volume":"31","author":"HH Lin","year":"2011","unstructured":"Lin HH et al. CCND1 1722 polymorphism and potential relevance to upper tract urothelial cancer. Anticancer Res. 2011;31(3):1043\u20137.","journal-title":"Anticancer Res"},{"issue":"11","key":"566_CR26","first-page":"4907","volume":"33","author":"WS Chang","year":"2013","unstructured":"Chang WS et al. Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer. Anticancer Res. 2013;33(11):4907\u201312.","journal-title":"Anticancer Res"},{"issue":"2","key":"566_CR27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.juro.2011.10.038","volume":"187","author":"M Roupret","year":"2012","unstructured":"Roupret M et al. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol. 2012;187(2):424\u20138.","journal-title":"J Urol"},{"issue":"5","key":"566_CR28","first-page":"2725","volume":"35","author":"WS Chang","year":"2015","unstructured":"Chang WS et al. Significant association of cyclo-oxygenase 2 genotypes with upper tract urothelial cancer. Anticancer Res. 2015;35(5):2725\u201330.","journal-title":"Anticancer Res"},{"issue":"4","key":"566_CR29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg2005","volume":"8","author":"M Esteller","year":"2007","unstructured":"Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286\u201398.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"566_CR30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1464-410X.2009.08696.x","volume":"104","author":"V Phe","year":"2009","unstructured":"Phe V, Cussenot O, Roupret M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009;104(7):896\u2013901.","journal-title":"BJU Int"},{"issue":"1","key":"566_CR31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2013.08.025","volume":"50","author":"S Monteiro-Reis","year":"2014","unstructured":"Monteiro-Reis S et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer. 2014;50(1):226\u201333.","journal-title":"Eur J Cancer"},{"key":"566_CR32","doi-asserted-by":"crossref","unstructured":"Xiong, G., et al., Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics, 2015:1\u201312.","DOI":"10.2217\/epi.15.34"},{"issue":"6","key":"566_CR33","first-page":"1863","volume":"8","author":"K Inoue","year":"2002","unstructured":"Inoue K et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002;8(6):1863\u201370.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"566_CR34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/sj.bjc.6605835","volume":"103","author":"CF Wu","year":"2010","unstructured":"Wu CF et al. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Br J Cancer. 2010;103(6):852\u201360.","journal-title":"Br J Cancer"},{"issue":"23","key":"566_CR35","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-10-0230","volume":"16","author":"T Kosaka","year":"2010","unstructured":"Kosaka T et al. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res. 2010;16(23):5814\u201323.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"566_CR36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-410X.2008.08292.x","volume":"104","author":"L Izquierdo","year":"2009","unstructured":"Izquierdo L et al. Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P\/GSK-3beta\/beta-catenin pathway. BJU Int. 2009;104(1):100\u20136.","journal-title":"BJU Int"},{"issue":"1","key":"566_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0463.2008.00859.x","volume":"116","author":"S Leibl","year":"2008","unstructured":"Leibl S et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008;116(1):27\u201332.","journal-title":"APMIS"},{"issue":"1","key":"566_CR38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.juro.2013.12.001","volume":"192","author":"YW Wang","year":"2014","unstructured":"Wang YW et al. Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. J Urol. 2014;192(1):242\u201351.","journal-title":"J Urol"},{"issue":"6","key":"566_CR39","first-page":"2439","volume":"30","author":"L Izquierdo","year":"2010","unstructured":"Izquierdo L et al. HER-2\/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res. 2010;30(6):2439\u201345.","journal-title":"Anticancer Res"},{"issue":"21","key":"566_CR40","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-09-1689","volume":"69","author":"CN Qian","year":"2009","unstructured":"Qian CN et al. Activation of the PI3K\/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res. 2009;69(21):8256\u201364.","journal-title":"Cancer Res"},{"issue":"7","key":"566_CR41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jclinpath-2012-201278","volume":"66","author":"PI Liang","year":"2013","unstructured":"Liang PI et al. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol. 2013;66(7):573\u201382.","journal-title":"J Clin Pathol"},{"issue":"12","key":"566_CR42","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.humpath.2013.07.008","volume":"44","author":"E Munari","year":"2013","unstructured":"Munari E et al. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Hum Pathol. 2013;44(12):2668\u201376.","journal-title":"Hum Pathol"},{"issue":"7","key":"566_CR43","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-04-1685","volume":"11","author":"K Nakanishi","year":"2005","unstructured":"Nakanishi K et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res. 2005;11(7):2583\u201390.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"566_CR44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.juro.2013.07.012","volume":"191","author":"LM Krabbe","year":"2014","unstructured":"Krabbe LM et al. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. J Urol. 2014;191(1):28\u201334.","journal-title":"J Urol"},{"issue":"1","key":"566_CR45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1464-410x.2000.00726.x","volume":"86","author":"T Kamai","year":"2000","unstructured":"Kamai T et al. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int. 2000;86(1):14\u20139.","journal-title":"BJU Int"},{"issue":"5","key":"566_CR46","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.urology.2014.07.050","volume":"84","author":"A Bagrodia","year":"2014","unstructured":"Bagrodia A et al. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014;84(5):1134\u201340.","journal-title":"Urology"},{"issue":"8","key":"566_CR47","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1464-410X.2010.09210.x","volume":"106","author":"HC Yeh","year":"2010","unstructured":"Yeh HC et al. Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int. 2010;106(8):1223\u20139.","journal-title":"BJU Int"},{"issue":"2","key":"566_CR48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.urolonc.2009.12.003","volume":"30","author":"S Scarpini","year":"2012","unstructured":"Scarpini S et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol. 2012;30(2):182\u20137.","journal-title":"Urol Oncol"},{"issue":"6","key":"566_CR49","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1464-410X.2009.09144.x","volume":"106","author":"K Uematsu","year":"2010","unstructured":"Uematsu K et al. Glucose-regulated protein 78 expression in urothelial carcinoma of the upper urinary tract. BJU Int. 2010;106(6):873\u20138.","journal-title":"BJU Int"},{"issue":"5","key":"566_CR50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.humpath.2008.10.010","volume":"40","author":"IG Jeong","year":"2009","unstructured":"Jeong IG et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol. 2009;40(5):668\u201377.","journal-title":"Hum Pathol"},{"key":"566_CR51","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1186\/1471-2407-14-836","volume":"14","author":"S Wu","year":"2014","unstructured":"Wu S et al. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. BMC Cancer. 2014;14:836.","journal-title":"BMC Cancer"},{"key":"566_CR52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2407-14-363","volume":"14","author":"CM Lu","year":"2014","unstructured":"Lu CM et al. A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis. BMC Cancer. 2014;14:363.","journal-title":"BMC Cancer"},{"issue":"6104","key":"566_CR53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.","journal-title":"Science"},{"issue":"5","key":"566_CR54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clgc.2015.02.009","volume":"13","author":"M Kurtoglu","year":"2015","unstructured":"Kurtoglu M et al. Elevating the horizon: emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma. Clin Genitourin Cancer. 2015;13(5):410\u201320. This article reviewed emerging genomic targets, most promising targeted therapies and novel clinical trial designs for urothelial carcinoma of bladder.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"566_CR55","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-09-3562","volume":"70","author":"SC Smith","year":"2010","unstructured":"Smith SC et al. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010;70(5):1753\u20138.","journal-title":"Cancer Res"},{"key":"566_CR56","doi-asserted-by":"crossref","unstructured":"S Kothari, D. Gustatafson, K Killian, J Costello, D C. Edelman, J Walling, P S. Meltzer, D Theodorescu, A Borghese. COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients. J Clin Oncol. 2015;33(suppl; abstr e15533).","DOI":"10.1200\/jco.2015.33.15_suppl.e15533"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-015-0566-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-015-0566-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-015-0566-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T12:07:22Z","timestamp":1567512442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-015-0566-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1007\/s11934-015-0566-y","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,13]]},"article-number":"12"}}